Paradoxically, Western pharmaceutical companies impose persistent price inflation on these medicines, often exceeding general inflation rates, while benefiting simultaneously from reduced production costs through outsourced API manufacturing and intense competition among Chinese suppliers. This dual advantage has made their business models unusually comfortable.

Read More